- Home
- TARA vs ACRS Comparison
TARA vs ACRS Comparison
Compare TARA & ACRS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TARA
- ACRS
- Stock Information
- Founded
- TARA N/A
- ACRS 2012
- Country
- TARA United States
- ACRS United States
- Employees
- TARA N/A
- ACRS N/A
- Industry
- TARA Biotechnology: Biological Products (No Diagnostic Substances)
- ACRS Biotechnology: Pharmaceutical Preparations
- Sector
- TARA Health Care
- ACRS Health Care
- Exchange
- TARA Nasdaq
- ACRS Nasdaq
- Market Cap
- TARA 196.8M
- ACRS 198.2M
- IPO Year
- TARA N/A
- ACRS 2015
- Fundamental
- Price
- TARA $5.12
- ACRS $2.56
- Analyst Decision
- TARA Strong Buy
- ACRS Strong Buy
- Analyst Count
- TARA 6
- ACRS 9
- Target Price
- TARA $19.80
- ACRS $9.25
- AVG Volume (30 Days)
- TARA 455.2K
- ACRS 1.3M
- Earning Date
- TARA 11-03-2025
- ACRS 11-06-2025
- Dividend Yield
- TARA N/A
- ACRS N/A
- EPS Growth
- TARA N/A
- ACRS N/A
- EPS
- TARA N/A
- ACRS N/A
- Revenue
- TARA N/A
- ACRS $16,789,000.00
- Revenue This Year
- TARA N/A
- ACRS N/A
- Revenue Next Year
- TARA N/A
- ACRS N/A
- P/E Ratio
- TARA N/A
- ACRS N/A
- Revenue Growth
- TARA N/A
- ACRS N/A
- 52 Week Low
- TARA $2.21
- ACRS $1.05
- 52 Week High
- TARA $10.48
- ACRS $5.17
- Technical
- Relative Strength Index (RSI)
- TARA 56.48
- ACRS 68.44
- Support Level
- TARA $4.96
- ACRS $2.24
- Resistance Level
- TARA $5.39
- ACRS $2.47
- Average True Range (ATR)
- TARA 0.30
- ACRS 0.22
- MACD
- TARA -0.10
- ACRS 0.04
- Stochastic Oscillator
- TARA 20.00
- ACRS 83.91
About TARA Protara Therapeutics Inc.
Protara Therapeutics Inc is committed to identifying and advancing transformative therapies for people with cancer and rare diseases. The company discovers, develops and delivers breakthrough therapies to people who have limited treatment options. Its portfolio includes its program, TARA-002, being developed for the treatment of lymphatic malformations, and intravenous (IV) choline chloride, a phospholipid substrate replacement therapy for the treatment of intestinal failure associated liver disease (IFALD).
About ACRS Aclaris Therapeutics Inc.
Aclaris Therapeutics Inc is a clinical-stage biopharmaceutical company that operates in the United States. It focuses on developing novel drug candidates for immuno-inflammatory diseases. The company operates in two reportable segments: therapeutics and contract research. The therapeutics segment is focused on identifying and developing inventive therapies to address unmet needs for immuno-inflammatory diseases, and the contract research segment is engaged in providing laboratory services. A majority of the company's revenue is derived from the therapeutics segment. The various drug candidates in its product pipeline are Zunsemetinib, which is an Oral MK2 Inhibitor; ATI-2138, an ITJ Inhibitor; Bosakitug, ATI-052, and Lepzacitinib.